This is a very odd characterization! Looking at Turing's 2014 10-K, I see this as a listed strategy: Focus on developing products to treat rare diseases charac

This is a very odd characterization! Looking at Turing's 2014 10-K, I see this as a listed strategy: Focus on developing products to treat rare diseases characterized by severe unmet medical needs. I also see several preclinical programs and product candidates. You must have missed those. Odd case, very strange.